Group 1 - The event "2025 Hebei Listed Companies Investor Online Collective Reception Day" was held on September 15, focusing on the collective performance explanation of the 2025 semi-annual reports [1] - Morning Light Bio (300138) reported a significant increase in R&D expenses in the first half of the year, primarily due to increased material costs associated with customized and application-oriented product development [1] - The company plans to maintain its R&D investment to drive product innovation and has obtained 11 drug registration certificates and 2 traditional Chinese medicine formula granule filings in the traditional Chinese medicine sector [1] Group 2 - Morning Light Bio is expanding its market through various methods such as centralized procurement, contract manufacturing, and agency, indicating a positive outlook for future market conditions [1]